Judith Derdelinckx1,2, Irene Nkansah1, Naomi Ooms1, Laura Van Bruggen1, Marie-Paule Emonds3, Liesbeth Daniëls3, Tatjana Reynders2, Barbara Willekens1,2, Patrick Cras2,4, Zwi N Berneman1,5, Nathalie Cools1,5. 1. Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VaxInfectio), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium. 2. Division of Neurology, Antwerp University Hospital, 2650 Edegem, Belgium. 3. Histocompatibility and Immunogenetics Laboratory, Red Cross-Flanders, 2650 Mechelen, Belgium. 4. Born Bunge Institute, Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium. 5. Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, 2650 Edegem, Belgium.
Abstract
BACKGROUND: When aiming to restore myelin tolerance using antigen-specific treatment approaches in MS, the wide variety of myelin-derived antigens towards which immune responses are targeted in multiple sclerosis (MS) patients needs to be taken into account. Uncertainty remains as to whether the myelin reactivity pattern of a specific MS patient can be predicted based upon the human leukocyte antigen (HLA) class II haplotype of the patient. METHODS: In this study, we analyzed the reactivity towards myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP) and proteolipid protein (PLP) peptides using direct interferon (IFN)-γ enzyme-linked immune absorbent spot (ELISPOT). Next, the HLA class II haplotype profile was determined by next-generation sequencing. In doing so, we aimed to evaluate the possible association between the precursor frequency of myelin-reactive T cells and the HLA haplotype. RESULTS: Reactivity towards any of the analyzed peptides could be demonstrated in 65.0% (13/20) of MS patients and in 60.0% (6/10) of healthy controls. At least one of the MS risk alleles HLA-DRB1*15:01, HLA-DQA1*01:02 and HLA-DQB1*06:02 was found in 70.0% (14/20) of patients and in 20.0% (2/10) of healthy controls. No difference in the presence of a myelin-specific response, nor in the frequency of myelin peptide-reactive precursor cells could be detected among carriers and non-carriers of these risk alleles. CONCLUSION: No association between HLA haplotype and myelin reactivity profile was present in our study population. This complicates the development of antigen-specific treatment approaches and implies the need for multi-epitope targeting in an HLA-unrestricted manner to fully address the wide variation in myelin responses and HLA profiles in a heterogeneous group of MS patients.
BACKGROUND: When aiming to restore myelin tolerance using antigen-specific treatment approaches in MS, the wide variety of myelin-derived antigens towards which immune responses are targeted in multiple sclerosis (MS) patients needs to be taken into account. Uncertainty remains as to whether the myelin reactivity pattern of a specific MS patient can be predicted based upon the human leukocyte antigen (HLA) class II haplotype of the patient. METHODS: In this study, we analyzed the reactivity towards myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP) and proteolipid protein (PLP) peptides using direct interferon (IFN)-γ enzyme-linked immune absorbent spot (ELISPOT). Next, the HLA class II haplotype profile was determined by next-generation sequencing. In doing so, we aimed to evaluate the possible association between the precursor frequency of myelin-reactive T cells and the HLA haplotype. RESULTS: Reactivity towards any of the analyzed peptides could be demonstrated in 65.0% (13/20) of MS patients and in 60.0% (6/10) of healthy controls. At least one of the MS risk alleles HLA-DRB1*15:01, HLA-DQA1*01:02 and HLA-DQB1*06:02 was found in 70.0% (14/20) of patients and in 20.0% (2/10) of healthy controls. No difference in the presence of a myelin-specific response, nor in the frequency of myelin peptide-reactive precursor cells could be detected among carriers and non-carriers of these risk alleles. CONCLUSION: No association between HLA haplotype and myelin reactivity profile was present in our study population. This complicates the development of antigen-specific treatment approaches and implies the need for multi-epitope targeting in an HLA-unrestricted manner to fully address the wide variation in myelin responses and HLA profiles in a heterogeneous group of MS patients.
Entities:
Keywords:
HLA class II genotype; antigen-specific treatment; multiple sclerosis; myelin responsiveness
Authors: V K Tuohy; M Yu; L Yin; J A Kawczak; J M Johnson; P M Mathisen; B Weinstock-Guttman; R P Kinkel Journal: Immunol Rev Date: 1998-08 Impact factor: 12.988
Authors: L Grau-López; D Raïch; C Ramo-Tello; M Naranjo-Gómez; A Dávalos; R Pujol-Borrell; F E Borràs; E Martínez-Cáceres Journal: Eur J Neurol Date: 2010-12-29 Impact factor: 6.089
Authors: Judith Field; Sharon R Browning; Laura J Johnson; Patrick Danoy; Michael D Varney; Brian D Tait; Kaushal S Gandhi; Jac C Charlesworth; Robert N Heard; Graeme J Stewart; Trevor J Kilpatrick; Simon J Foote; Melanie Bahlo; Helmut Butzkueven; James Wiley; David R Booth; Bruce V Taylor; Matthew A Brown; Justin P Rubio; Jim Stankovich Journal: PLoS One Date: 2010-10-26 Impact factor: 3.240
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Loukas Moutsianas; Luke Jostins; Ashley H Beecham; Alexander T Dilthey; Dionysia K Xifara; Maria Ban; Tejas S Shah; Nikolaos A Patsopoulos; Lars Alfredsson; Carl A Anderson; Katherine E Attfield; Sergio E Baranzini; Jeffrey Barrett; Thomas M C Binder; David Booth; Dorothea Buck; Elisabeth G Celius; Chris Cotsapas; Sandra D'Alfonso; Calliope A Dendrou; Peter Donnelly; Bénédicte Dubois; Bertrand Fontaine; Lars Fugger; An Goris; Pierre-Antoine Gourraud; Christiane Graetz; Bernhard Hemmer; Jan Hillert; Ingrid Kockum; Stephen Leslie; Christina M Lill; Filippo Martinelli-Boneschi; Jorge R Oksenberg; Tomas Olsson; Annette Oturai; Janna Saarela; Helle Bach Søndergaard; Anne Spurkland; Bruce Taylor; Juliane Winkelmann; Frauke Zipp; Jonathan L Haines; Margaret A Pericak-Vance; Chris C A Spencer; Graeme Stewart; David A Hafler; Adrian J Ivinson; Hanne F Harbo; Stephen L Hauser; Philip L De Jager; Alastair Compston; Jacob L McCauley; Stephen Sawcer; Gil McVean Journal: Nat Genet Date: 2015-09-07 Impact factor: 38.330